Large-scale testing (Phase 3)Not Yet RecruitingNCT07711002
What this trial is testing
Saruparib in Combination With Physician's Choice of ARPI in Patients With mHSPC Previously Treated With Docetaxel or 177Lu-PSMA Therapy Without Disease Progression and PSA ≥ 0.2 ng/mL (EvoPAR-PR05)
Who this might be right for
Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
AstraZeneca 1,330